Viela Bio Announces Start of First Clinical Trial
GAITHERSBURG, Md., Aug. 20, 2018 /PRNewswire/ -- Viela Bio announced today the start of the company's first clinical trial, a phase 1, first-in-human clinical trial of VIB9600, which is being developed for the treatment of adult patients with immune mediated diseases. Following the...
Read more »